Small trial sees potential for new rectal cancer drug - Hindustan Times

All patients in a rectal cancer drug trial were in remission after six months. Experts say it's 'revolutionary' but bigger, more diverse studies are needed. | Health

After receiving an experimental drug called dostarlimab in a small trial, all 12 participants experienced complete remission. Doctors say this is the first time that such a cancer drug has had a 100%… [+4202 chars]

full article...